PCV13 pneumococcal vaccine
Selected indexed studies
- A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (STRIDE-6). (Clin Infect Dis, 2024) [PMID:39082735]
- A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. (Pediatr Infect Dis J, 2024) [PMID:38535409]
- 13-valent pneumococcal conjugate vaccine (PCV13). (Hum Vaccin, 2011) [PMID:21941097]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (STRIDE-6). (2024) pubmed
- A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. (2024) pubmed
- 13-valent pneumococcal conjugate vaccine (PCV13). (2011) pubmed
- Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. (2023) pubmed
- Pneumococcal immunity and PCV13 vaccine response in SOT-candidates and recipients. (2021) pubmed
- A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination. (2021) pubmed
- Potentiating pneumococcal glycoconjugate vaccine PCV13 with saponin adjuvant VSA-1. (2022) pubmed
- PCV13 vaccine prevents pneumococcal biofilms without affecting Staphylococcus aureus population within the polymicrobial biofilm. (2024) pubmed
- Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers. (2024) pubmed
- Global distribution and characteristics of pneumococcal serotypes in adults. (2025) pubmed